Genotype of Immunologically Hot or Cold Tumors Determines the Antitumor Immune Response and Efficacy by Fully Virulent Retargeted oHSV

Genotype of Immunologically Hot or Cold Tumors Determines the Antitumor Immune Response and Efficacy by Fully Virulent Retargeted oHSV

We report on the efficacy of the non-attenuated HER2-retargeted oHSV named R-337 against the immunologically hot CT26-HER2 tumor, and an insight into the basis of the immune protection. Preliminarily, we conducted an RNA immune profiling and immune cell content characterization of CT26-HER2 tumor in...

Full description

Bibliographic Details
Main Authors: Tatiana Gianni, Valerio Leoni, Mara Sanapo, Federico Parenti, Daniela Bressanin, Catia Barboni, Anna Zaghini, Gabriella Campadelli-Fiume, Andrea Vannini
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Viruses
Subjects:
oncolytic virus
oncolytic herpes simplex virus
retargeting
HER2
tumor genotype
vaccination
Online Access:https://www.mdpi.com/1999-4915/13/9/1747

Internet

https://www.mdpi.com/1999-4915/13/9/1747

Similar Items